Description

• General description: Phenytoin is an antiepileptic drug used in the prevention and treatment of seizures. This analytical reference standard is suitable as starting material for the preparation of calibrators and controls in phenytoin testing by GC/MS or LC-MS/MS. Phenytoin is sold under the trade name Dilantin®.
• Application: Advanced Separation and Extraction of Anticonvulsants: Phenytoin solution is utilized in the fabrication of surface molecularly imprinted polymer membranes. This innovative method enhances the separation and extraction of phenytoin, phenobarbital, and lamotrigine, significantly improving the precision and efficiency of drug monitoring in clinical and research settings (Zhao et al., 2024).LC-MS/MS Quantification for Drug Delivery: A sensitive LC-MS/MS method has been developed for the quantification of phenytoin and its major metabolite. This method is applied to both intravenous and intranasal delivery systems, enhancing our understanding of the pharmacokinetics and effectiveness of phenytoin as an anticonvulsant medication (Prentice et al., 2022).Clinical Decision Support for Pharmacogenomics: Phenytoin is involved in the appraisal and development of evidence-based clinical decision support systems. This research integrates pharmacogenomic data to optimize perioperative drug use, providing tailored therapeutic strategies based on genetic profiles, particularly for managing epilepsy treatments (Borden et al., 2021).Electromembrane Extraction Technique: The development of an electromembrane extraction method followed by capillary electrophoresis for phenytoin determination in exhaled breath condensate. This technique offers a non-invasive approach for therapeutic drug monitoring, critical for ensuring effective seizure control in epilepsy patients (Seyfinejad et al., 2020).Drug Crystallization Inhibition: Research into the use of polymer nanogels as reservoirs for phenytoin has shown potential in inhibiting drug crystallization. This approach could revolutionize drug delivery systems by maintaining the stability and bioavailability of phenytoin, enhancing its therapeutic efficacy for treating neurological disorders (Li et al., 2019).
• Legal Information: CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany